Waverley Pharma, Inc. (TSE:WAVE) has released an update.
Waverley Pharma Inc. has shifted its business strategy after facing challenges in the competitive generic oncology drug market, resulting in the sale of its US commercial rights for two drugs back to the manufacturer. The company is now refocusing its efforts on the development of an innovative PARP-1 inhibitor, signaling a new direction in its quest to provide safe and effective therapeutics.
For further insights into TSE:WAVE stock, check out TipRanks’ Stock Analysis page.
